Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial… Read more
Aardvark Therapeutics, Inc. Common Stock (AARD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.151x
Based on the latest financial reports, Aardvark Therapeutics, Inc. Common Stock (AARD) has a cash flow conversion efficiency ratio of -0.151x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.52 Million) by net assets ($122.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aardvark Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Aardvark Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aardvark Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aardvark Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LapWall Oyj
HE:LAPWALL
|
0.154x |
|
LENSAR Inc
NASDAQ:LNSR
|
0.290x |
|
Silitech Technology Corp
TW:3311
|
0.013x |
|
Aero Win Technology Corp
TW:8222
|
0.027x |
|
Hites S.A.
SN:HITES
|
0.142x |
|
Oneview Healthcare PLC
PINK:ONVVF
|
-0.431x |
|
Standard Engineering Technology Limited
NSE:SGLTL
|
N/A |
|
YoungQin International Co
TWO:2755
|
0.106x |
Annual Cash Flow Conversion Efficiency for Aardvark Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-54.64 Million | $-18.09 Million | 0.331x | +97.79% |
| 2023-12-31 | $-34.80 Million | $-5.82 Million | 0.167x | -55.68% |
| 2022-12-31 | $-27.92 Million | $-10.54 Million | 0.378x | -- |